Next Article in Journal
Transporter-Mediated Delivery of Small Molecule Drugs to the Brain: A Critical Mechanism That Can Advance Therapeutic Development for Ischemic Stroke
Next Article in Special Issue
Dendritic Cell Vaccines for Cancer Immunotherapy: The Role of Human Conventional Type 1 Dendritic Cells
Previous Article in Journal
Alternatives to Biological Skin in Permeation Studies: Current Trends and Possibilities
Previous Article in Special Issue
Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells—An Update
Open AccessReview

Endoplasmic Reticulum-Associated Degradation-Dependent Processing in Cross-Presentation and Its Potential for Dendritic Cell Vaccinations: A Review

Laboratory of Physiological Chemistry, Faculty of Pharmacy, Takasaki University of Health and Welfare, Takasaki, Gunma 370-0033, Japan
*
Author to whom correspondence should be addressed.
Pharmaceutics 2020, 12(2), 153; https://doi.org/10.3390/pharmaceutics12020153
Received: 15 January 2020 / Revised: 10 February 2020 / Accepted: 12 February 2020 / Published: 13 February 2020
(This article belongs to the Special Issue Dendritic Cell Vaccines)
While the success of dendritic cell (DC) vaccination largely depends on cross-presentation (CP) efficiency, the precise molecular mechanism of CP is not yet characterized. Recent research revealed that endoplasmic reticulum (ER)-associated degradation (ERAD), which was first identified as part of the protein quality control system in the ER, plays a pivotal role in the processing of extracellular proteins in CP. The discovery of ERAD-dependent processing strongly suggests that the properties of extracellular antigens are one of the keys to effective DC vaccination, in addition to DC subsets and the maturation of these cells. In this review, we address recent advances in CP, focusing on the molecular mechanisms of the ERAD-dependent processing of extracellular proteins. As ERAD itself and the ERAD-dependent processing in CP share cellular machinery, enhancing the recognition of extracellular proteins, such as the ERAD substrate, by ex vivo methods may serve to improve the efficacy of DC vaccination. View Full-Text
Keywords: dendritic cell; cross-presentation; major histocompatibility class I; endoplasmic reticulum-associated degradation; molecular chaperone; DC vaccination dendritic cell; cross-presentation; major histocompatibility class I; endoplasmic reticulum-associated degradation; molecular chaperone; DC vaccination
Show Figures

Graphical abstract

MDPI and ACS Style

Imai, J.; Ohashi, S.; Sakai, T. Endoplasmic Reticulum-Associated Degradation-Dependent Processing in Cross-Presentation and Its Potential for Dendritic Cell Vaccinations: A Review. Pharmaceutics 2020, 12, 153. https://doi.org/10.3390/pharmaceutics12020153

AMA Style

Imai J, Ohashi S, Sakai T. Endoplasmic Reticulum-Associated Degradation-Dependent Processing in Cross-Presentation and Its Potential for Dendritic Cell Vaccinations: A Review. Pharmaceutics. 2020; 12(2):153. https://doi.org/10.3390/pharmaceutics12020153

Chicago/Turabian Style

Imai, Jun; Ohashi, Sayaka; Sakai, Takahiro. 2020. "Endoplasmic Reticulum-Associated Degradation-Dependent Processing in Cross-Presentation and Its Potential for Dendritic Cell Vaccinations: A Review" Pharmaceutics 12, no. 2: 153. https://doi.org/10.3390/pharmaceutics12020153

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop